In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Second-largest CRO Seeks Initial Public Offering In The U.S.

This article was originally published in PharmAsia News

Executive Summary

Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18

You may also be interested in...



ShangPharma Biologics Head Mitchell Reff On Biologics R&D In China: An Interview With PharmAsia News

ShangPharma’s new Chief Biologic Officer Mitchell Reff discusses the company’s expansion into biologics and his views on biologics development in China.

Will WuXi Benefit From Rival ShangPharma Going Private?

China’s second largest CRO ShangPharma is likely to go private after a proposal from its founder, and some say the exit may also help its larger rival WuXi PharmaTech.

Chinese CRO ShangPharma Opens New Facility To Support Lilly's Pipeline

China’s second-largest CRO opens new Shanghai facility to support its largest client.

Related Content

UsernamePublicRestriction

Register

SC073237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel